<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    3492164
   </pmid>
   <datecreated>
    <year>
     1987
    </year>
    <month>
     02
    </month>
    <day>
     17
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1987
    </year>
    <month>
     02
    </month>
    <day>
     17
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2006
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-4819
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       106
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        1987
       </year>
       <month>
        Feb
       </month>
      </pubdate>
     </journalissue>
     <title>
      Annals of internal medicine
     </title>
     <isoabbreviation>
      Ann. Intern. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
    </articletitle>
    <pagination>
     <medlinepgn>
      196-204
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      The effects of broad-spectrum antibiotic and placebo therapy in patients with chronic obstructive pulmonary disease in exacerbation were compared in a randomized, double-blinded, crossover trial. Exacerbations were defined in terms of increased dyspnea, sputum production, and sputum purulence. Exacerbations were followed at 3-day intervals by home visits, and those that resolved in 21 days were designated treatment successes. Treatment failures included exacerbations in which symptoms did not resolve but no intervention was necessary, and those in which the patient's condition deteriorated so that intervention was necessary. Over 3.5 years in 173 patients, 362 exacerbations were treated, 180 with placebo and 182 with antibiotic. The success rate with placebo was 55% and with antibiotic 68%. The rate of failure with deterioration was 19% with placebo and 10% with antibiotic. There was a significant benefit associated with antibiotic. Peak flow recovered more rapidly with antibiotic treatment than with placebo. Side effects were uncommon and did not differ between antibiotic and placebo.
     </abstracttext>
    </abstract>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Anthonisen
      </lastname>
      <forename>
       N R
      </forename>
      <initials>
       NR
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Manfreda
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Warren
      </lastname>
      <forename>
       C P
      </forename>
      <initials>
       CP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hershfield
      </lastname>
      <forename>
       E S
      </forename>
      <initials>
       ES
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Harding
      </lastname>
      <forename>
       G K
      </forename>
      <initials>
       GK
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Nelson
      </lastname>
      <forename>
       N A
      </forename>
      <initials>
       NA
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Ann Intern Med
    </medlineta>
    <nlmuniqueid>
     0372351
    </nlmuniqueid>
    <issnlinking>
     0003-4819
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Bacterial Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Drug Combinations
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      26787-78-0
     </registrynumber>
     <nameofsubstance>
      Amoxicillin
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      564-25-0
     </registrynumber>
     <nameofsubstance>
      Doxycycline
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      723-46-6
     </registrynumber>
     <nameofsubstance>
      Sulfamethoxazole
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      738-70-5
     </registrynumber>
     <nameofsubstance>
      Trimethoprim
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      8064-90-2
     </registrynumber>
     <nameofsubstance>
      Trimethoprim-Sulfamethoxazole Combination
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Amoxicillin
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Bacterial Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Doxycycline
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Combinations
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dyspnea
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Lung Diseases, Obstructive
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Random Allocation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Respiratory Sounds
     </descriptorname>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sputum
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Sulfamethoxazole
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Trimethoprim
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Trimethoprim-Sulfamethoxazole Combination
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1987
     </year>
     <month>
      2
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1987
     </year>
     <month>
      2
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1987
     </year>
     <month>
      2
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     3492164
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

